News | September 11, 2007

September 12, 2007 — Tangerine peel could help in the fight against certain cancers, researchers recently reported.
Human cancer cells, which contain an enzyme called P450 CYP1B1, were destroyed by a compound contained in tangerine peel, Salvestrol Q40, scientists at Leicester School of Pharmacy found.
The findings may offer a new approach to uncovering a treatment for cancers such as breast, lung, prostate and ovarian cancer, the scientists said.
Medicinal chemist Dr. Hoon L. Tan said, "It is very exciting to find a compound in food that can target cancers specifically.”
"Indeed, the depletion of salvestrols in the modern diet is due to the fact that many people no longer eat the skin of fruits and this may be a major contributory factor to the increasing incidence of some cancers in the human population," he added.
The breakthrough was being presented at the British Pharmaceutical Conference held in Manchester.
But he warned that the research was still in its early days and many tests will be needed before reaching the clinical trial stage, which could take between five and seven years.
The researchers have formed a private company, Nature's Defence Investments, to protect and promote their research, with the potential of designing a natural anti-cancer alternative based on the new technology.
For more information: www.naturesdefence.com


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now